Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives

Contraception. 1995 Jan;51(1):53-8. doi: 10.1016/0010-7824(94)00002-e.

Abstract

Coagulation factors, 11-dehydro-TxB2 (metabolite of TxA2) and 6-keto-PGF1 alpha (metabolite of PGI2) levels in 87 women who were treated for 9 months with oral contraceptives (OC) containing low doses of oestrogens and progestogens (Triquilar, Trinovum or Cilest) were investigated. In plasma, increases in F I, II, VII, VIII-c and 11-dehydro-TxB2 levels, but no modification of 6-keto-PGF1 alpha were observed. In urine, FPA concentration rose, but no change occurred in 11-dehydro-TxB2 and 6-keto-PGF1 alpha levels. No marked difference between the 3 OC preparations were noted. These data, and particularly the large increase of 11-dehydro-TxB2 (p < 0.01) suggest that a hypercoagulable state persists in low dosage OC users.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / blood
  • Adult
  • Analysis of Variance
  • Contraceptives, Oral / pharmacology*
  • Ethinyl Estradiol / pharmacology
  • Factor VII / analysis
  • Factor VIII / analysis
  • Female
  • Fibrinogen / analysis
  • Humans
  • Levonorgestrel / pharmacology
  • Norethindrone / pharmacology
  • Norgestrel / analogs & derivatives
  • Norgestrel / pharmacology
  • Prothrombin / analysis
  • Thromboxane B2 / analogs & derivatives*
  • Thromboxane B2 / blood

Substances

  • Contraceptives, Oral
  • Norgestrel
  • Ethinyl Estradiol
  • Thromboxane B2
  • 6-Ketoprostaglandin F1 alpha
  • Levonorgestrel
  • 11-dehydro-thromboxane B2
  • Factor VII
  • Prothrombin
  • Factor VIII
  • Fibrinogen
  • norgestimate
  • Norethindrone